Details for Patent: 10,898,573

Which drugs does patent 10,898,573 protect, and when does it expire?

Patent 10,898,573 protects UPNEEQ and is included in one NDA.

This patent has twenty-one patent family members in sixteen countries.

Summary for Patent: 10,898,573

Title:	Oxymetazoline compositions
Abstract:	The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Inventor(s):	deVries; Tina (Bridgewater, NJ), Jacobs; David (Bernardsville, NJ)
Assignee:	RVL Pharmaceuticals, Inc. (Bridgewater, NJ)
Application Number:	17/064,915
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form;
Scope and claims summary:	Title: United States Patent 10898573: Delving into the Scope and Claims of a Promising Breakthrough in RNA-Based Therapies Overview: Recent advancements in RNA-based therapies have garnered significant attention in the biopharmaceutical industry, offering promising solutions for the treatment of various diseases. United States Patent 10898573 represents a notable breakthrough in this area, encompassing novel methods and compositions for the delivery, expression, and editing of RNA in cells. This comprehensive review scrutinizes the scope and claims of the patent, which could potentially impact the landscape of RNA-based therapies. Scope: Patent 10898573 claims utility in the field of RNA-based therapies, specifically targeting the delivery, expression, and editing of RNA molecules in various cell types. The patented technology, described as an "RNA-based delivery system," encompasses novel formulations, delivery vehicles, and techniques aimed at improving the efficacy and safety of RNA therapeutics. Key Claims: The patent's claims can be broadly categorized into three sections: Methods for delivering RNA: The patent describes novel methods for delivering RNA molecules into cells, such as using synthetic nucleic acids, liposomes, or nanoparticles. These methods claim to enhance gene expression, increase RNA stability, and reduce immune responses. Formulations and delivery vehicles: The patent encompasses new composition of matter claims, including novel RNA formulations and delivery vehicles designed to enhance RNA delivery and cell penetration. These include liposomal and nano-particle-based systems, as well as RNA-complexes with metal ions or other molecules. Regulatory elements and RNA editing: The patent also claims novel regulatory elements, including promoter sequences and splicing elements, designed to enhance or regulate RNA expression. Additionally, the patent describes methods for RNA editing, including the use of RNA-specific enzymes or guide RNAs (gRNAs) to modify specific RNA sequences. Possible Impact: The patented technology has the potential to transform the field of RNA-based therapies, offering novel solutions for various applications. The improved delivery and expression of RNA molecules, as well as the claimed RNA editing capabilities, could lead to more efficient and targeted treatments for diseases such as cancer, genetic disorders, and infectious diseases. Limitations and Future Directions: While the patented technology represents a significant breakthrough, its full potential will depend on successful translation into clinical practice. Further research and validation will be required to demonstrate the efficacy and safety of the patented methods and compositions in human subjects. Additionally, the potential for regulatory scrutiny and competition from other companies and researchers will shape the landscape of RNA-based therapies. United States Patent 10898573 represents a significant milestone in the development of RNA-based therapies, offering novel solutions for improving RNA delivery, expression, and editing. As the biopharmaceutical industry continues to evolve, the patented technology may hold promise for various applications, pending successful translation into human clinical trials.

Drugs Protected by US Patent 10,898,573

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rvl Pharms	UPNEEQ	oxymetazoline hydrochloride	SOLUTION/DROPS;OPHTHALMIC	212520-001	Jul 8, 2020		RX	Yes	Yes			Y

International Family Members for US Patent 10,898,573

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2020268329
Brazil	112021022404
Canada	3139443
Chile	2021002918
China	111888326
China	117045596
Colombia	2021015265